Armenia - engleză - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

acs dobfar spa - ceftazidime (ceftazidime pentahydrate), avibactam (avibactam sodium) - powder for solution for infusion - 2g+ 0,5g

Armenia - engleză - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

acs dobfar spa - ceftazidime (ceftazidime pentahydrate), avibactam (avibactam sodium) - powder for solution for infusion - 2g+ 0,5g

Canada - engleză - Health Canada

sterimax inc - ceftazidime (ceftazidime pentahydrate) - powder for solution - 1g - ceftazidime (ceftazidime pentahydrate) 1g - third generation cephalosporins

Canada - engleză - Health Canada

sterimax inc - ceftazidime (ceftazidime pentahydrate) - powder for solution - 2g - ceftazidime (ceftazidime pentahydrate) 2g - third generation cephalosporins

Canada - engleză - Health Canada

sterimax inc - ceftazidime (ceftazidime pentahydrate) - powder for solution - 6g - ceftazidime (ceftazidime pentahydrate) 6g - third generation cephalosporins

Canada - engleză - Health Canada

sterimax inc - ceftazidime (ceftazidime pentahydrate) - powder for solution - 3g - ceftazidime (ceftazidime pentahydrate) 3g - third generation cephalosporins

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftazidime pentahydrate 1.164 g equivalent to ceftazidime 1.0 g - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to ceftazidime 1.0 g excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycoside in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, for example infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. - severe ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis. - infections associted with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftazidime pentahydrate 2.329 g equivalent to ceftazidime 2.0 g - powder for injection - 2 g - active: ceftazidime pentahydrate 2.329 g equivalent to ceftazidime 2.0 g excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycoside in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, for example infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. - severe ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis. - infections associted with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Australia - engleză - Department of Health (Therapeutic Goods Administration)

omegapharm - ceftazidime pentahydrate, quantity: 2349 mg (equivalent: ceftazidime, qty 2000 mg) - injection, powder for - excipient ingredients: sodium carbonate - omegapharm ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for e

Australia - engleză - Department of Health (Therapeutic Goods Administration)

omegapharm - ceftazidime pentahydrate, quantity: 1175 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - omegapharm ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for e